| Identification | Back Directory | [Name]
PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- | [CAS]
847950-09-8 | [Synonyms]
Lck Inhibitor
6-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one
6-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one
PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- | [Molecular Formula]
C31H30N8O | [MDL Number]
MFCD18782603 | [MOL File]
847950-09-8.mol | [Molecular Weight]
530.62 |
| Chemical Properties | Back Directory | [Boiling point ]
809.1±75.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
crystalline solid | [pka]
7.87±0.42(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
TC-S 7003 is a novel, potent and orally active inhibitor of Lymphocyte Specific Kinase (Lck). | [in vivo]
Lck 抑制剂 (0-60 mg/kg；口服每天一次；从第 9 天到第 17 天) 显示出对关节炎的剂量依赖性抑制[1]。
Lck 抑制剂 (口服5 mg/kg) 处理显示Cmax、AUC0-∞、tmax和F%分别为82 ng/mL、862 ng h/mL，和 17%，分别[1]。 | Animal Model: | Male Lewis rat (adjuvant-inducedarthritis model) [1] | | Dosage: | 0, 30, and 60 mg/kg | | Administration: | P.o.; once daily; from day 9 today 17 | | Result: | Showed a dose-dependent inhibition of arthritis, with an ED50 estimated at 24 mg/kg.
|
| Animal Model: | Sprague-Dawley Rats[1] | | Dosage: | P.o. (Pharmacokinetic Analysis) | | Administration: | 5 mg/kg | | Result: | The Cmax, AUC0-∞, tmax and F% were 82 ng/mL, 862 ng h/mL, and 17%, respectively.
|
| [storage]
Store at -20°C |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|